CN103739671B - A kind of polyethyleneglycol modified suppression nuclear Factor-Kappa B polypeptide and application thereof - Google Patents
A kind of polyethyleneglycol modified suppression nuclear Factor-Kappa B polypeptide and application thereof Download PDFInfo
- Publication number
- CN103739671B CN103739671B CN201310748682.XA CN201310748682A CN103739671B CN 103739671 B CN103739671 B CN 103739671B CN 201310748682 A CN201310748682 A CN 201310748682A CN 103739671 B CN103739671 B CN 103739671B
- Authority
- CN
- China
- Prior art keywords
- polypeptide
- kappa
- nuclear factor
- polyethyleneglycol modified
- arthritis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 45
- 102000003945 NF-kappa B Human genes 0.000 title claims abstract description 43
- 108010057466 NF-kappa B Proteins 0.000 title claims abstract description 43
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 42
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 42
- 230000001629 suppression Effects 0.000 title claims abstract description 31
- 229920001223 polyethylene glycol Polymers 0.000 title claims description 40
- 239000002202 Polyethylene glycol Substances 0.000 title claims description 32
- 239000003112 inhibitor Substances 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract description 10
- 230000002265 prevention Effects 0.000 abstract description 6
- 238000002560 therapeutic procedure Methods 0.000 abstract description 2
- 238000009509 drug development Methods 0.000 abstract 1
- 239000002547 new drug Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 24
- 241000700159 Rattus Species 0.000 description 21
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- 206010003246 arthritis Diseases 0.000 description 12
- 102000008186 Collagen Human genes 0.000 description 10
- 108010035532 Collagen Proteins 0.000 description 10
- 229920001436 collagen Polymers 0.000 description 10
- 239000002671 adjuvant Substances 0.000 description 9
- 238000010171 animal model Methods 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 230000008961 swelling Effects 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 210000003423 ankle Anatomy 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 206010039361 Sacroiliitis Diseases 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 208000009386 Experimental Arthritis Diseases 0.000 description 5
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 5
- 230000002917 arthritic effect Effects 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 229960000485 methotrexate Drugs 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 102000002734 Collagen Type VI Human genes 0.000 description 3
- 108010043741 Collagen Type VI Proteins 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 210000002683 foot Anatomy 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000003607 modifier Substances 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 101710115512 Nuclear receptor coactivator 5 Proteins 0.000 description 2
- 241001111421 Pannus Species 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 206010048873 Traumatic arthritis Diseases 0.000 description 2
- 206010047115 Vasculitis Diseases 0.000 description 2
- 230000003356 anti-rheumatic effect Effects 0.000 description 2
- 239000003435 antirheumatic agent Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Chemical compound NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 2
- 108010084652 homeobox protein PITX1 Proteins 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 210000001258 synovial membrane Anatomy 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- PBQVHWFDMNCCIH-KNJAVFAGSA-N (4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;n,n-dimethyl-1-phenothiazin-10-ylpropan-2-amine;n-(4-hydroxyphenyl)acetamide;phosphoric acid;hydrochloride Chemical compound Cl.OP(O)(O)=O.CC(=O)NC1=CC=C(O)C=C1.C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1.C([C@H]1C(N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC PBQVHWFDMNCCIH-KNJAVFAGSA-N 0.000 description 1
- JAJIPIAHCFBEPI-UHFFFAOYSA-N 9,10-dioxoanthracene-1-sulfonic acid Chemical compound O=C1C2=CC=CC=C2C(=O)C2=C1C=CC=C2S(=O)(=O)O JAJIPIAHCFBEPI-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- 206010007710 Cartilage injury Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- VVNCNSJFMMFHPL-VKHMYHEASA-N D-penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 101000974353 Mus musculus Nuclear receptor coactivator 5 Proteins 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- JLLJTMHNXQTMCK-UBHSHLNASA-N Phe-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CC1=CC=CC=C1 JLLJTMHNXQTMCK-UBHSHLNASA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000124033 Salix Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000008407 joint function Effects 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 108010024654 phenylalanyl-prolyl-alanine Proteins 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- -1 polyoxyethylene Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 229940061969 rheumatrex Drugs 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- GECHUMIMRBOMGK-UHFFFAOYSA-N sulfapyridine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=CC=CC=N1 GECHUMIMRBOMGK-UHFFFAOYSA-N 0.000 description 1
- 229960002211 sulfapyridine Drugs 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present invention relates to pharmaceutical field, be specifically related to that there is suppression nuclear Factor-Kappa B, the polypeptide of energy prevention and therapy rheumatoid arthritis.Its sequence is mPEG-SC
20k-KRSGGGFPAAV is brand-new sequence, and useful benefit of the present invention can be used for treating rheumatoid arthritis, has potential new drug development value.
Description
technical field:
The present invention relates to pharmaceutical field, be specifically related to the nuclear Factor-Kappa B peptide inhibitor for prevention and therapy or prevention rheumatoid arthritis.
background technology:
Rheumatoid arthritis (rheumatoid arthritis, RA) is one of clinical modal inflammatory arthropathy and main disability-causing factor.Be about 0.5%-1.0% in the whole world, the morbidity of RA is about 0.4% in China.RA can betide any age, and with advancing age, sickness rate also increases thereupon.Women the age occurred frequently be 45-55 year, sex and RA onset relation are close, and the ratio of men and women is about 1:3.RA is the chronic systemic inflammation disease that a kind of cause of disease not yet understands, for main clinical manifestation, belongs to autoimmune inflammatory disease with pathology outside chronic, symmetry, many synovial joints inflammation and joint.Patient often with hand or wrist pain and swelling (particularly the swelling at wrist back), for onset symptoms, do not alleviate by Symptoms last, though common symptomatic treatment can relief of symptoms, usually because medication is irregular or in shortage and cause symptom repeatedly.Can occur during disease progression that obvious morning stiff, usually can reach more than 1 hour, and constantly increase the weight of; There is certain joint function disturbance simultaneously.
The cause of disease of rheumatoid arthritis and pathogenesis are not yet completely clear, and its basic pathology feature is vasculitis and synovitis.Intraarticular synovial membrane blood vessel hyperplasia, forms pannus, causes synovial membrane to thicken, ooze out and increase, and secretion cytokine profiles, invades cartilage and cause bone damage.All erodables are organized also to the flesh chamber around it, ligament, stndon sheath and muscle etc., thus affects the stable of joint, easily joint deformity occur and occur dysfunction.Vasculitis also can invade each organs and tissues in the whole body, forms systemic disease.
The medicine of current treatment RA is divided into two large classes: control symptom medicine and control disease medicine.Due to RA etiology unknown, therefore there is no the medicine that can be rated as and control disease now.The antirheumatic controlling symptom is divided into four classes: one, non-steroidal anti-inflammatory drugs, and be commonly referred to a line medicine, this kind of medicament categories is various, nearly tens of kinds, domestic market.Two, steroid hormone, hormone is an extraordinary pain stop and anti-inflammation medicine, but is used alone for a long time and can not improves the state of an illness, bring many side effects on the contrary, transitionality before hormone does medication onset slowly as two wires is with being fine, but consumption is little, and the time is unsuitable long.Heavier in the state of an illness, with the patient of extra-articular manifestation, short impacts, and necessary when combining two wires medicine treatment.Three, act on antirheumatic slowly, be commonly referred to two wires medicine, so-called slow effect cartridge bag draws together antimalarial drug, golden salt, Trolovol and willow nitrogen sulfapyridine, and their treatment RA onsets are slow, and long term has certain mitigation to the RA state of an illness, therefore feelings of also pretending illness improve medicine.Four, immunosuppressor: conventional have Rheumatrex, endoxan, azathioprine, trypterygine, Stem of Orientoine etc.
In the biotechnological formulation for the treatment of RA, studying more is clinically exactly the antagonist of nuclear Factor-Kappa B (NF-κ B).Nuclear Factor-Kappa B is that one is extensively present in intracellular nuclear factor, and with the generation of inflammation in sacroiliitis, cartilage injury, the formation of cell migration and pannus has important relation.Take nuclear Factor-Kappa B as action target spot, the new way of the diseases such as treatment of arthritis may be become.Non-steroidal anti-inflammatory drugs, glucocorticosteroid, glycosaminoglycan and Novel protease body inhibitor etc. find the activation that all can suppress nuclear Factor-Kappa B.In addition, nuclear Factor-Kappa B decoy ODN and siRNA interference treatment also achieve gratifying achievements.
KRSGGGFPAAV is a brand-new sequence, and the research in early stage shows, this polypeptide confirms to have good resisting rheumatoid disease sacroiliitis effect through In vitro and in vivo activity evaluation repeatedly, can significantly suppress NF-Κ B active.But the transformation period of aforementioned polypeptides is short, intending with the administration of clinical people is intravenous drip every day, and this brings certain misery to patient.
In bibliographical information, modifying molecular structure or transforming is solve the common method that the transformation period is shorter, need successive administration problem, wherein be most widely used with chemically modified, conventional chemical modifier has polyoxyethylene glycol (polye thylene glycol, PEG), dextran, polyamino acid, condensing model etc.PEG has nontoxic, non-immunogenicity, good water solubility feature, by FDA (FDA) accreditation as the auxiliary material of medicine and modifier.Protein drug is after PEG modifies; molecular weight increases, and the filterability of renal glomerulus reduces, and the barrier action of PEG protects protein not easily by proteolytic enzymes hydrolize; decrease the generation of neutralizing antibody, these all contribute to the prolongation of protein drug biological half-life simultaneously.The protein drug list marketing of existing multiple PEG modification at present.But PEG modifies the biologic activity that simultaneously also may affect protein, it affects size and modifier, it is relevant to modify the character of condition and protein itself.For concrete protein, its best modification need be decided by the protein of preparation PEG modification and bioactivity research.The PEG of synthesized micromolecule polypeptide modifies research and starts late, but has caused the concern of many investigators.
summary of the invention:
The present invention seeks to the feature for existing NF-κ B antagonist, design the NF-κ B polypeptide antagonist of brand-new sequence, be more applicable for clinical application.
Technical solution of the present invention is to provide a kind of polyethyleneglycol modified suppression nuclear Factor-Kappa B polypeptide, and its sequence is mPEG-SC
20K-KRSGGGFPAAV, and the application in treatment or prevention medicine for treating rheumatoid arthritis.
beneficial outcomes:
Polyethyleneglycol modified suppression nuclear Factor-Kappa B peptide sequence mPEG-SC in the present invention
20K-KRSGGGFPAAV, can targeted inhibition nuclear Factor-Kappa B, the effect of the physiology that Tumor suppression mecrosis factor receptors produces or pathology, reaches the effect of prevention or treatment rheumatoid arthritis.
Through great many of experiments, contriver knows that polyethyleneglycol modified suppression nuclear Factor-Kappa B polypeptide can suppress the development of adjuvant type rat kind rheumatic arthritis and DBA/1 mouse collagen type rheumatoid arthritis, experiment in vivo proves to have the arthritic effect of significant treatment similar rheumatism type, and few side effects, the few cost of consumption reduces.Illustrate that the polyethyleneglycol modified suppression nuclear Factor-Kappa B polypeptide that the present invention designs is scientific, rational, feasible and effective, can as treatment or prevention medicine for treating rheumatoid arthritis.
Embodiment
The present invention relates to polypeptide to be synthesized by the biochemical (Shanghai) Co., Ltd. of gill.
Embodiment 1
Polyethyleneglycol modified suppression nuclear Factor-Kappa B polypeptide immanoprotection action in collagen-induced mouse arthritis animal model
Build collagen type mouse arthritis animal model, study the therapeutic action of polyethyleneglycol modified suppression nuclear Factor-Kappa B polypeptide to mouse collagen Induced Arthritis (collagen induced arthritis, CIA).Adopt mouse as animal subject, SPF level DBA/1 mouse 90 (is provided by Shanghai western pul-Bi Kai laboratory animal company limited (Sino-British SIPPR Lab. Animal Ltd), animal productiong ticket number: SCXK (Shanghai) 2008-0016), male, 7-8 week age, body weight is 18-22 g, be divided into 6 groups at random, Normal group respectively, model control group, low middle high 3 the dosage groups (5,10,20mg/kg) of peptide inhibitor 1 and positive drug control group (methotrexate 2 mg/kg).Except normal group, within the 0th day, each experimental group sets up mouse CIA model, and method is chicken cartilage II Collagen Type VI (c II) becomes 4 mg/ml solution with 0.1 mol/l acetate dissolution, in 4 DEG C of refrigerator overnight.Experimental day is fully emulsified with complete Freund's adjuvant (CFA) equal-volume containing 4 mg/ml Myeobaeterium tuberculosis strain H37Rv with II Collagen Type VI, after DBA/1 mouse anesthesia, often only inject emulsifying agent 50 μ l in its afterbody intracutaneous and carry out sensitization, after fully emulsified with II Collagen Type VI (c II) of 4 mg/ml and incomplete Freund's adjuvant (IFA) equal-volume after 21 d, carry out immunity again with the emulsifying agent of same dose in afterbody.Modeling the 30th d plays subcutaneous administrations: 3 dosage groups (5,10,20mg/kg) of polypeptide: every day twice, continuous 10 days; Positive drug control group (methotrexate 2 mg/kg): every five days once, continuous 3 times; Normal group and model control group (physiological saline): continuous 10 days.Respectively within after modeling the 21st day to the 70th day every 3 days, weighing in, Joint scores, detect left and right metapedes ankle diameter to observe medicine to the arthritic impact of mouse collagen type respectively.
Result: after modeling, mouse is compared with normal mouse, latter 27th day of immunity, CIA mouse foot pawl is red and swollen, and arthritis index scoring is increased, and model group 45-60 days is swelling peak, and model group started body weight from the 35th day to be increased hardly, and also there is decline in the later stage slightly.Polyethyleneglycol modified suppression nuclear Factor-Kappa B polypeptide immanoprotection action concrete outcome in collagen-induced mouse arthritis animal model is as follows:
Polyethyleneglycol modified suppression nuclear Factor-Kappa B polypeptide is on the impact of the left whole pawl swelling of mouse collagen type sacroiliitis, positive controls, the polyethyleneglycol modified left back ankle diameter of suppression nuclear Factor-Kappa B polypeptide high, medium and low dosage group compare with model group, all have pole significant difference (P<0.01) experimental result to have statistical significance.Polyethyleneglycol modified suppression nuclear Factor-Kappa B polypeptide is on the impact of the right whole pawl swelling of mouse collagen type sacroiliitis, positive controls, the polyethyleneglycol modified right back ankle diameter of suppression nuclear Factor-Kappa B polypeptide high, medium and low dosage group compare with model group, all have pole significant difference (P<0.01), experimental result has statistical significance.Polyethyleneglycol modified suppression nuclear Factor-Kappa B polypeptide is on the impact of collagen type arthritic mice clinical score, the scoring of polypeptide basic, normal, high dosage group four limbs is significantly lower than model control group (P < 0.01), compare pole significant difference with model control group, experimental result has statistical significance.Polyethyleneglycol modified suppression nuclear Factor-Kappa B polypeptide affects collagen type arthritic mice body weight, polypeptide high, medium and low dosage group body weight is significantly higher than model control group (P < 0.01), compare pole significant difference with model control group, experimental result has statistical significance.
Conclusion: polyethyleneglycol modified suppression nuclear Factor-Kappa B polypeptide has therapeutic action to mouse collagen type sacroiliitis.
Embodiment 2
Polyethyleneglycol modified suppression nuclear Factor-Kappa B polypeptide is to immanoprotection action in adjuvant type rat arthritis animal model
Build adjuvant type rat arthritis animal model, study the therapeutic action of polyethyleneglycol modified suppression nuclear Factor-Kappa B polypeptide to adjuvant-induced arthritis (Adjuvant arthritis, AA) rat.Adopt rat as animal subject, SPF level SD rat 90 (is provided by Shanghai western pul-Bi Kai laboratory animal company limited (Sino-British SIPPR Lab. Animal Ltd), animal productiong ticket number: SCXK (Shanghai) 2008-0016), male, body weight is 140 g-160 g, be divided into 6 groups at random, Normal group respectively, model control group, low middle high 3 the dosage groups (5 of polyethyleneglycol modified suppression nuclear Factor-Kappa B polypeptide, 10,20 mg/kg) and positive drug control group (methotrexate 1 mg/kg).Except normal group, within the 0th day, each experimental group sets up rat AA model, and method is that injection of wasting time fully afterwards in the left side of rat causes experimental animal model of CFA induced adjuvant arthritis in rats containing mycobacterium tuberculosis (H37RA, 10 mg/ml) complete Freund's adjuvant 0.08 ml of deactivation.Modeling plays subcutaneous administrations on the 10th day: 3 dosage groups (5,10,20mg/kg) of polypeptide: every day twice, continuous 10 days; Positive drug control group (methotrexate 1 mg/kg): every five days once, continuous 3 times; Normal group and model control group (physiological saline): continuous 10 days.Respectively at after modeling the 8th, 11,14,17,20,23 and 26 days, weigh in, Joint scores, detect left and right metapedes ankle diameter to observe medicine to the arthritic impact of rat adjuvant type respectively.
Result: after modeling, rat is compared with normal rat, the left back foot of AA rat can produce primary arthritis rapidly, occurs obvious swelling, and with festering; Start to occur post-traumatic arthritis after about 10 d of right back foot, the score value of scoring increases gradually; Ear's blood vessel hyperplasia is obvious simultaneously, obviously red and swollen; There is swelling in caudal articular process.Polyethyleneglycol modified suppression nuclear Factor-Kappa B polypeptide immanoprotection action in adjuvanticity rat arthritis animal model, concrete outcome is as follows:
Polyethyleneglycol modified suppression nuclear Factor-Kappa B polypeptide is on the impact of rat primary sacroiliitis foot pawl swelling, the left back ankle diameter of basic, normal, high dosage group of rat positive controls, polyethyleneglycol modified suppression nuclear Factor-Kappa B polypeptide compares with model group, has pole significant difference (P<0.01); The polyethyleneglycol modified left back ankle diameter of suppression nuclear Factor-Kappa B polypeptide basic, normal, high dosage group compares with model group, and all have significant difference (P<0.05), experimental result has statistical significance.Polyethyleneglycol modified suppression nuclear Factor-Kappa B polypeptide is on the impact of rat post-traumatic arthritis foot pawl swelling, rat positive controls, the polyethyleneglycol modified right back ankle diameter of suppression nuclear Factor-Kappa B polypeptide basic, normal, high dosage group compare with model group, have significant difference (P<0.05).Polyethyleneglycol modified suppression nuclear Factor-Kappa B polypeptide is on the impact of adjuvant type rats with arthritis clinical score, the scoring of polypeptide basic, normal, high dosage group four limbs, significantly lower than model control group (P < 0.05), all has statistical significance with model control group comparing difference.Polyethyleneglycol modified suppression nuclear Factor-Kappa B polypeptide affects adjuvant type rats with arthritis body weight, polypeptide high, medium and low dosage group body weight is significantly higher than model control group (P < 0.05), all has statistical significance with model control group comparing difference.
Conclusion: polyethyleneglycol modified suppression nuclear Factor-Kappa B polypeptide has therapeutic action to AA rat arthritis.
SEQUENCE LISTING
<110> timely snow, sieve
The suppression nuclear Factor-Kappa B polypeptide that <120> mono-kind is polyethyleneglycol modified and application thereof
<130>
<160> 1
<170> PatentIn version 3.3
<210> 1
<211> 11
<212> PRT
<213> artificial sequence
<400> 1
mPEG-SC
20K-Lys Arg Ser Gly Gly Gly Phe Pro Ala Ala Val
1 5 10
Claims (2)
1. polyethyleneglycol modified suppression nuclear Factor-Kappa B polypeptide, is characterized in that its sequence is mPEG-SC-KRSGGGFPAAV.
2. a kind of polyethyleneglycol modified nuclear factor kappa B inhibitor polypeptide according to claim 1, is characterized in that the molecular weight of described mPEG-SC is 20000.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310748682.XA CN103739671B (en) | 2013-12-31 | 2013-12-31 | A kind of polyethyleneglycol modified suppression nuclear Factor-Kappa B polypeptide and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310748682.XA CN103739671B (en) | 2013-12-31 | 2013-12-31 | A kind of polyethyleneglycol modified suppression nuclear Factor-Kappa B polypeptide and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103739671A CN103739671A (en) | 2014-04-23 |
| CN103739671B true CN103739671B (en) | 2015-08-26 |
Family
ID=50496755
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310748682.XA Expired - Fee Related CN103739671B (en) | 2013-12-31 | 2013-12-31 | A kind of polyethyleneglycol modified suppression nuclear Factor-Kappa B polypeptide and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103739671B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105504022A (en) * | 2016-02-02 | 2016-04-20 | 苏州普罗达生物科技有限公司 | NF-kappa B polypeptide and application thereof |
| CN107857800B (en) * | 2017-11-09 | 2020-05-05 | 北京赛升药业股份有限公司 | Long-acting integrin inhibitor and application thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101307094B (en) * | 2008-03-21 | 2011-09-28 | 中国人民解放军第三军医大学第三附属医院 | Novel nuclear factor -kappa B p65 subunit antagonizing polypeptide |
| CN102417540A (en) * | 2011-11-21 | 2012-04-18 | 中国药科大学 | Polyethylene glycol-modified integrin blocking agent HM-3 and application thereof |
| CN102492656B (en) * | 2011-12-16 | 2014-12-10 | 白银博赛宁生物科技有限公司 | High-flux anti-tumor drug screening cell model based on STAT3 and NF-kB two-signal channel serving as target, as well as building and application of high-flux anti-tumor drug screening cell model |
-
2013
- 2013-12-31 CN CN201310748682.XA patent/CN103739671B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN103739671A (en) | 2014-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104127859B (en) | The application of polypeptide in preparation treatment or prevention medicine for treating rheumatoid arthritis | |
| CN103739670A (en) | Polyethylene glycol modified polypeptide for inhibiting tumor necrosis factor-alpha and application of polypeptide | |
| CN103739671B (en) | A kind of polyethyleneglycol modified suppression nuclear Factor-Kappa B polypeptide and application thereof | |
| CN103772489B (en) | Nf-KB peptide inhibitor 5 and application thereof | |
| CN103819540B (en) | Nf-KB peptide inhibitor and application thereof | |
| CN103772491B (en) | Nf-KB peptide inhibitor 3 and application thereof | |
| CN103739669B (en) | A kind of suppression interleukin-6 polypeptide and application thereof | |
| CN103739673B (en) | A kind of polyethyleneglycol modified suppression interleukin-6 polypeptide and application thereof | |
| CN103739677B (en) | A kind of suppression nuclear Factor-Kappa B polypeptide and application thereof | |
| CN103772492B (en) | Nf-KB peptide inhibitor 4 and application thereof | |
| CN103254291B (en) | Tumor necrosis factor-alpha polypeptide inhibitors and application thereof | |
| CN103285373A (en) | Preparation method and application of tumor necrosis factor (TNF)-alpha polypeptide inhibitor | |
| CN103265619A (en) | Tumor necrosis factor-alpha polypeptide inhibitor and application thereof | |
| CN105061583A (en) | Peripheral interleukin 35 polypeptide and application thereof | |
| CN103893161A (en) | Application of syringic acid-(4-hydroxyl-3,5-dimethoxybenzoic acid) in preparation of medicine for preventing and treating rheumatoid arthritis | |
| CN110101845B (en) | Application of irisin in preparing medicine for preventing and treating postoperative cognitive dysfunction and brain diseases mediated by blood brain barrier damage | |
| CN103288921A (en) | Polypeptide inhibitor of vascular endothelial growth factor 2 tyrosine kinase and application thereof | |
| CN103288922A (en) | Tumor necrosis factor (TNF)-alpha polypeptide inhibitor and application thereof | |
| CN103923182A (en) | Interleukin-6 polypeptide inhibitor and its application | |
| CN103751169A (en) | Application of 3'-methoxy benzyl-3,5-dimethoxy-4-(3'-methoxy benzyloxy)benzoate in preparation of drugs for treating or preventing rheumatoid arthritis | |
| CN103923185A (en) | Interleukin-6 polypeptide inhibitor and its application | |
| CN103923180A (en) | Interleukin-6 polypeptide inhibitor and its application | |
| CN103923183A (en) | Interleukin-6 polypeptide inhibitor and its application | |
| CN103751168A (en) | Application of 3'-methoxy benzyl-4-hydroxy-3,5-dimethoxy-benzoate in preparation of drugs for treating or preventing rheumatoid arthritis | |
| CN105504022A (en) | NF-kappa B polypeptide and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: GUO XIANGHUA Free format text: FORMER OWNER: LUO RUIXUE Effective date: 20150728 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C53 | Correction of patent for invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Guo Xianghua Inventor before: Luo Ruixue |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: LUO RUIXUE TO: GUO XIANGHUA |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20150728 Address after: 272000 Shandong province Jining Guhuai Road No. 79 (Affiliated Hospital of Jining Medical College) Applicant after: Guo Xianghua Address before: 639 No. 211198 Jiangsu province Nanjing city Jiangning District University City longmian Road Applicant before: Luo Ruixue |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150826 Termination date: 20161231 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |